Blood and Histopathological Biomarkers of Immune-related Adverse Effects of Treatment with Immune Checkpoint Inhibitors

Immune checkpoint inhibitors have been a recent major breakthrough in the management of tumors.They have broadened the scope of management in medical oncology,which has been heavily dependent on chemotherapy.Immune checkpoint inhibitors have renewed the hope of many patients for a more effective treatment.However,Immune checkpoint inhibitors are also associated with a variety of adverse effects,most commonly immunerelated adverse events,and these are often different from the known chemotherapy-induced toxicities.Hence,there is a need to identify specific biomarkers which are able to predict or diagnose these immune-related adverse events.

Sintilimab-induced autoimmune diabetes:A case report and review of the literature

BACKGROUND With the widespread application of immune checkpoint inhibitor(ICI)therapy,the number of immune-related adverse effects(irAEs)has increased over the years.Autoimmune diabetes mellitus(DM)is a rare irAEs of ICIs and can be troublesome and life threatening.CASE SUMMARY We report a 78-year-old woman with no history of diabetes who presented with hyperglycemia up to 23.4 mmol/L(random blood glucose level)after 14 courses of sintilimab.Hemoglobin A1c was 8.2%,fasting insulin was 0.29 mIU/mL,and fasting C-peptide was decreased to a level with negative autoantibodies.Combing her medical history and laboratory examination,she was diagnosed with programmed cell death(PD)-1-inhibitor-induced,new-onset autoimmune DM.After controlling her blood glucose,she was treated with daily insulin by subcutaneous injection.She was allowed to continue anti-PD-1 therapy and she still obtained some therapeutic efficacy.We also reviewed some published cases(n=36)of PD-1/PD-ligand 1(PD-L1)inhibitor-induced DM.We also discuss potential pathogenic mechanisms,clinical features,prognostic markers(βcell antibodies,human leukocyte antigen type,PD-L1 Level)of this rare adverse effect.CONCLUSION It is important for all clinicians to be aware of DM as an irAEs of ICIs.

Tuning Martensitic Phase Transition by Non-Magnetic Atom Vacancy in MnCoGe Alloys and Related Giant Magnetocaloric Effect

The effects of non-magnetic atom vacancy on structural, martensitic phase transitions and the corresponding magnetocMoric effect in MnCoGel-x alloys are investigated using x-ray diffraction and magnetic measurements. The introduction of non-magnetic atom vacancy leads to the decrease of the martensitic transition temperature and realizes a temperature window where magnetic and martensitic phase transitions can be tuned together. Moreover, the giant magnetocaloric effect accompanied with the coupled magnetic-structural transition is ob- tained. It is observed that the peak values of magnetic entropy change of MnCoGeo.97 are about -13.9, -35.1 and -47.4J.kg-1K-1 for △H = 2, 5, 7T, respectively.

Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase

Objective To explore the impact of patient reported outcome of tyrosine kinase inhibitor(TKI)related side effects on daily life in Chinese patients with chronic myceloid leukemia(CML)in the chronic phase(CP).Methods From May to November in 2014。

INVERSE SCATTERING PROBLEM FOR ONE-DIMENSIONAL SCHRDINGER OPERATORS RELATED TO THE GENERAL STARK EFFECT

This paper disccusses the inverse scattering problem for one-dimensional Schrodinger operatorsrelated to the general Stark effect. We provide a ganeral framework which can be applied both to theStark-effect operator and the ordinary Schrodinger operator.